Disclaimer: This article is for informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.
Overview
A guide to the active ingredient and Canadian brand landscape for this specialized metabolic medication.
Zepbound® is a brand-name pharmaceutical containing the active ingredient tirzepatide. In Canada, this molecule is a "dual agonist," meaning it targets two specific pathways in the body. While Zepbound® is a primary brand for this formulation, Mounjaro® is the other competing Canadian brand that utilizes the same active ingredient for metabolic management.
vailable strengths and formats of the medication currently authorized for sale within the Canadian market.
In Canada, Zepbound® is available as a solution for subcutaneous injection. It is typically provided in a single-dose pre-filled pen (KwikPen®) or single-dose vials. The available strengths include:
- 2.5 mg / 0.5 mL
- 5 mg / 0.5 mL
- 7.5 mg / 0.5 mL
- 10 mg / 0.5 mL
- 12.5 mg / 0.5 mL
- 15 mg / 0.5 mL
How Zepbound® Works
How this medication activates two distinct hormone receptors to support natural metabolic balance in the body.
This medication works at a biological level by mimicking two natural hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). By binding to these receptors, the medication influences how the body processes nutrients and manages hunger signals. It enhances the body's natural response to food intake and helps regulate internal metabolic timing.
Dosage Instructions of Zepbound®
Safety-first guidelines on how to administer this weekly injection as directed by a healthcare professional.
Treatment usually begins with a low "starter" dose and is gradually increased by a healthcare provider. The medication is injected once weekly, at any time of day, with or without food. Common injection sites include the abdomen, thigh, or upper arm. Users should rotate the injection site with every dose to maintain skin health.
Storage Instructions
Best practices for keeping your medication effective by maintaining the correct temperature and light exposure. Temperature: Store in the refrigerator between 2°C and 8°C. Freezing: Do not freeze; if the medication has been frozen, discard it. Light: Keep the pen in its original carton to protect it from light. Room Temp: If necessary, a single pen can be kept at room temperature (up to 30°C) for up to 21 days.
Side Effects of Zepbound®
A summary of common physical responses and serious health signals that require immediate medical attention.
Nausea, Diarrhea, Vomiting
Severe, persistent stomach pain
Fatigue, Constipation
Signs of an allergic reaction (rash, swelling)
Decreased appetite
Vision changes or rapid heartbeat
Important Safety Information About Zepbound®
Essential Health Canada warnings regarding family medical history and specific health conditions to monitor closely.
Health Canada has issued a Serious Warning regarding the risk of thyroid C-cell tumours. This medication is contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should report any lumps in the neck or difficulty swallowing to their doctor immediately.
Drug Interactions
Information on how this medication may affect the absorption of other drugs or supplements in your system.
Because Zepbound® slows the rate at which the stomach empties (gastric emptying), it may affect how other oral medications are absorbed. This is particularly important for:
- Oral Contraceptives: Their effectiveness may be reduced; consult a doctor about alternative methods.
- Insulin Secretagogues: Combining these can increase the risk of low blood sugar.
- Health Supplements: Always disclose all vitamins or herbal products to your pharmacist.
Brands & DIN Number of Zepbound®
Brand Names
Mounjaro®
DIN (Drug Identification Numbers)
02557509
Key Takeaways
- 1Active Ingredient: Contains tirzepatide, a dual-action peptide.
- 2Administration: Weekly subcutaneous injection via pre-filled pen.
- 3Regulatory: Health Canada approved and requires a prescription.
- 4Mechanism: Mimics GIP and GLP-1 hormones to regulate metabolic pathways.
- 5Storage: Requires refrigeration but can stay at room temperature for limited periods.